The notices it replaced
- Reissues: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 2 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 5 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 10 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-19-270.
Who won it before
1,178 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $373,294,982 in first-year total cost, median $225,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]82
- Special Emphasis Panel[ZRG1 OTC-T (10)]65
- Special Emphasis Panel[ZRG1 ETTN-G (12)]59
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 BCMB-G (10)]34
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC11
- L2 DIAGNOSTICS, LLC10
- MEDOSOME BIOTEC, LLC9
- MICROBIOTIX, INC7
- FIREBIRD BIOMOLECULAR SCIENCES, LLC6
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | A small molecule integrin activator to enhance cord blood transplant2R42HL129612-02 | MARATHI, UPENDRAVANDERSLICE, PETER | 7 HILLS PHARMA, LLC, TX | $935,957 | ZRG1 |
| 2020 | Caduceus Quest: An interactive digital media resource to promote knowledge of reproductive health and STEM2R44GM133290-02A1 | GILLIAM, MELISSA L.PARSONS, TIMOTHY | RESILIENT GAMES STUDIO, LLC, IL | $781,659 | ZRG1 |
| 2020 | Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing2R42GM116479-02A1 | MEYSTRE, STEPHANE | CLINACUITY,INC., SC | $759,330 | ZRG1 |
| 2020 | A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement2R42HL134418-03A1 | BLUESTEIN, DANNY | POLYNOVA CARDIOVASCULAR, INC, NY | $719,175 | ZRG1 |
| 2020 | Integrated Platform for Mass-Spectrometric Studies of Protein Structure2R42GM121133-02 | BERN, MARSHALL WAYNE | PROTEIN METRICS, LLC, CA | $613,930 | ZRG1 |
| 2020 | Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH1R42HL151045-01 | AHSAN, FAKHRUL | VASCULAR BIOSCIENCES, CA | $330,004 | ZRG1 |
| 2020 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis1R41EY030391-01A1 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $309,102 | ZRG1 |
| 2020 | Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections1R41AI145759-01A1 | SPELLBERG, BRAD J | EXBAQ LLC, MD | $300,000 | ZRG1 |
| 2020 | Tumor bed implant for simultaneous heat and radiation of resectable brain tumors1R41CA239815-01A1 | STAUFFER, PAUL RATH | MAE CONSULTING GROUP LLC, NH | $300,000 | ZRG1 |
| 2020 | Development of Broad Spectrum Antifungal Agents1R41AI149960-01 | WRIGHT, DENNIS L. | QUERCUS MOLECULAR DESIGN, LLC, CT | $300,000 | ZRG1 |
| 2020 | Antimetabolites for Acute Myeloid Leukemias1R41CA247113-01 | WRIGHT, DENNIS L. | QUERCUS MOLECULAR DESIGN, LLC, CT | $300,000 | ZRG1 |
| 2020 | Regenerative Therapy for Corneal Endothelial Dystrophies and Injuries1R42EY031196-01 | DAS, HIRANMOY | RASHMIVU, LLC, OH | $300,000 | ZRG1 |
| 2020 | Developing high throughput measurement of thiopurine in DNA by mass spectrometry1R41GM136093-01 | TAO, W. ANDY | TYMORA ANALYTICAL OPERATIONS, LLC, IN | $299,975 | ZRG1 |
| 2020 | Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries1R41HL151025-01 | BOIRE, TIMOTHY C | VENOSTENT, INC., TX | $299,910 | ZRG1 |
| 2020 | Evaluation of a peptide that inhibits the activation of NOX2 and the generation of reactive oxygen species in protection against acute lung injury1R41HL145848-01A1 | FEINSTEIN, SHELDON IFISHER, ARON B. | PEROXITECH, LLC, PA | $299,866 | ZRG1 |
| 2020 | Non-Invasive Oropharynx Appliance to Maintain Airway Patency1R41HL150933-01 | DURAND, DOMINIQUE M | ANEMED INC, OH | $299,743 | ZRG1 |
| 2020 | Using Targeted Lipid Nanoparticles to Deliver Chemotherapeutic Agents against Pancreatic Cancer1R41CA247009-01 | LAMBROS, MARIA | DORICPHARMA LLC, CA | $299,559 | ZRG1 |
| 2020 | Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa1R41AI149922-01 | HEUCK, ALEJANDRO PABLOMOIR, DONALD T | MICROBIOTIX, INC, MA | $299,449 | ZRG1 |
| 2020 | Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)1R41AI149940-01 | AUCOIN, DAVID PRAYCHAUDHURI, SYAMAL X | INBIOS INTERNATIONAL, INC., WA | $299,112 | ZRG1 |
| 2020 | Next-generation precision medicine for targeting recombination-deficient cancers1R41CA239983-01A1 | POMERANTZ, RICHARD T | RECOMBINATION THERAPEUTICS, LLC, PA | $298,959 | ZRG1 |
| 2020 | Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity1R41AI149951-01 | MAMULA, MARK J | L2 DIAGNOSTICS, LLC, CT | $298,911 | ZRG1 |
| 2020 | Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood.1R41GM136084-01 | MILLER, CASS T | REDBUD LABS, INC., NC | $296,954 | ZRG1 |
| 2020 | Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells1R41AI149920-01 | GALARZA-MUNOZ, GADDIEL | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC., TX | $283,667 | ZRG1 |
| 2020 | Development of a vaccine to prevent Pneumocystis pneumonia1R41AI145416-01A1 | DOWNES, MICHAEL ROBERTNORRIS, KAREN A | NXT BIOLOGICS, INC., GA | $272,439 | ZRG1 |
| 2020 | Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning1R42ES031993-01 | ROSE, JASON JTEJERO BRAVO, JESUS | GLOBIN SOLUTIONS, INC., PA | $249,993 | ZRG1 |
| 2020 | Feelix @ Home: Testing and optimization of a smart stethoscope for home use to monitor changes in lung status of individuals with chronic conditions1R42HL147728-01A1 | BUSCH-VISHNIAC, ILENE JOYELHILALI, MOUNYA | SONAVI LABS, INC., MD | $236,489 | ZRG1 |
| 2020 | Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents1R41CA247058-01 | MISHRA, SANKET | GRANNUS THERAPEUTICS LLC, IN | $233,195 | ZRG1 |
| 2020 | Novel QcrB Inhibitors for the Treatment of Tuberculosis1R41AI145514-01A1 | HIPSKIND, PHILIP ARTHUR | LGENIA, INC., IN | $225,343 | ZRG1 |
| 2020 | A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation1R41EY030382-01A1 | GRAMATIKOV, BORISSHAKA, JUSTIN | REBISCAN, LLC, MA | $225,000 | ZRG1 |
| 2020 | A platform for engineering peptide ligase for building next generation peptide therapeutics.1R41GM136037-01 | ABATE, ADAM R. | SCRIBE BIOSCIENCES, INC., CA | $225,000 | ZRG1 |
| 2020 | Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels1R41EY031219-01 | PAULUS, YANNIS MANTAS | PHOTOSONOX LLC, MI | $225,000 | ZRG1 |
| 2020 | Pharmacological chaperones for the treatment of Open-Angle Glaucoma1R41EY031203-01 | MAKLEY, LEAH NICOLE | VIEWPOINT THERAPEUTICS, INC., CA | $225,000 | ZRG1 |
| 2020 | Portable, affordable, quantitative microchip electrophoresis system for integrated anemia and hemoglobin variant testing1R41HL151015-01 | GALEN, PETER | HEMEX HEALTH, INC., OR | $225,000 | ZRG1 |
| 2020 | Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure1R41HL151235-01 | ROY-CHAUDHURY, PRABIRRYCHNOVSKY, STEVEN | ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., CA | $225,000 | ZRG1 |
| 2020 | Development of EFTX-001 to target KRAS mutations in cancer1R41CA246848-01 | PECOT, CHAD V | ENFUEGO THERAPEUTICS INC., NC | $224,995 | ZRG1 |
| 2020 | Non-invasive Detection of Cerebral Aneurysm Recurrence after Endovascular Treatment Using Automated Image Processing1R41NS115253-01 | CHEN, PENG ROCLEE, TOM | MEDICAL INNOVATORS COMPANY, LLC, TX | $224,981 | ZRG1 |
| 2020 | A Mobile/Web-based Training Curriculum for Disseminating Best Practices for the Care of Newborns with Neonatal Opioid Withdrawal Syndrome1R41DA050408-01 | KONG, ALBERTA SUM-YUPRATT-CHAVEZ, HEATHER ASMITH, DAVID RANDOLPH | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $224,919 | ZRG1 |
| 2020 | Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease1R41AI149916-01 | SEAVEY, MATTHEW | PELICAN THERAPEUTICS, INC., TX | $224,713 | ZRG1 |
| 2020 | Programming Metabolically Fit TILs for Immunotherapy1R41CA239952-01A1 | MEHROTRA, SHIKHAR | LIPO-IMMUNO TECH, LLC, SC | $224,559 | ZRG1 |
| 2020 | An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment1R41AI149954-01 | DAVIDSON, BRUCE A.KUTSCHER, HILLIARD | POP BIOTECHNOLOGIES, INC, NY | $223,797 | ZRG1 |
| 2020 | Rifampin potentiation in NTM1R41AI145461-01A1 | TIMMINS, GRAHAM S | SPINCEUTICA, INC., NM | $205,299 | ZRG1 |
| 2019 | A Novel Probiotic Platform to Treat Necrotizing Enterocolitis2R44GM122130-02 | BAILEY, MICHAEL TBESNER, GAIL EGOODMAN, STEVEN DTREBLEY, JOE | SCIOTO BIOSCIENCES, INC., IN | $1,150,153 | ZRG1 |
| 2019 | The Bumps: A Device for Rapid, Non-Invasive Quantification of Touch Sensation2R42TR000462-04A1 | KENNEDY, WILLIAM RSIMONE, DONALD | NEURO DEVICES, INC., MN | $1,011,590 | ZRG1 |
| 2019 | Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy2R42CA224646-02 | SRIDHAR, SRINIVAS | THERANANO, LLC, MA | $1,007,156 | ZRG1 |
| 2019 | Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes2R42AI131784-02 | WAGNER, DAVID H. | OP-T-MUNE, INC., CO | $1,000,000 | ZRG1 |
| 2019 | IND enabling development of LGM2605 as adjuvant treatment for asthma2R42AI132012-02 | HACZKU, ANGELASIELECKI, THAIS MOTRIA | LIGNAMED, LLC, PA | $1,000,000 | ZRG1 |
| 2019 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis2R42AI122666-03 | ADHIKARI, RAJAN PHAKAMI, RAMIN M.NELSON, DANIEL C. | INTEGRATED BIOTHERAPEUTICS, INC., MD | $999,997 | ZRG1 |
| 2019 | Preclinical Development of OCF001 for Treatment of Yeast Infections2R42AI131792-02A1 | SMITH, JAMES LEIF | SANO CHEMICALS, INC, TX | $983,345 | ZRG1 |
| 2019 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents2R42AI126971-03A1 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $972,475 | ZRG1 |
| 2019 | Visual biofeedback to reduce head motion during MRI scans1R44MH122066-01 | DECKARD, TODD WILLIAMDOSENBACH, NICOFAIR, DAMIEN A | TURING MEDICAL TECHNOLOGIES INC, MO | $966,084 | ZRG1 |
| 2019 | Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease2R42HL133633-02A1 | FERGUSON, THOMAS BRUCE | RFPI, LLC, NC | $963,313 | ZRG1 |
| 2019 | An Automated Patient Chart Error Detection System for Radiation Therapy2R42CA195819-02A1 | XIA, JUNYI | INFONDRIAN, LLC, IA | $894,987 | ZRG1 |
| 2019 | Stem Cells for Treating Acute Stroke1R42NS112070-01 | GRANDE, ANDREW WKUZMIN-NICHOLS, NICOLE A.LOW, WALTER C | SANERON CCEL THERAPEUTICS, INC., FL | $843,689 | ZRG1 |
| 2019 | Application of PPODA-QT for embolization of aneurysms2R42NS097069-02A1 | BECKER, TIM | ANEUVAS TECHNOLOGIES, INC., AZ | $763,805 | ZRG1 |
| 2019 | 3D-Printed Superhydrophobic-Tipped Optical Fiber for Targeted Periodontal Photodynamic Therapy2R44DE026083-03 | XU, QIANFENG | SINGLETO2 THERAPEUTICS, LLC, NJ | $761,878 | ZRG1 |
| 2019 | Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons2R42DA041959-02 | MEHALSO, ROBERT | SENSODX II, LLC, NY | $760,245 | ZRG1 |
| 2019 | Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics2R42AI131823-02 | POLEJAEVA, IRINA A.WU, HUA | SAB CAPRA, LLC, UT | $758,090 | ZRG1 |
| 2019 | Automated Intestinal Electrical Stimulation for Diabetes2R42DK100212-02A1 | CHEN, JIANDE | TRANSTIMULATION RESEARCH, INC., OK | $749,185 | ZRG1 |
| 2019 | Novel antibacterial agents derived from natural products2R42AI118104-02 | PRIESTLEY, NIGEL D | PROMILIAD BIOPHARMA, INC., MT | $746,516 | ZRG1 |
| 2019 | BlueBox: A Complete Code Blue Data Recorder, Phase II2R42GM113463-02 | CHANG, RUEY-KANG | NEOVATIVE, INC., CA | $723,986 | ZRG1 |
| 2019 | Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker2R42CA228159-02 | CARDONES, ADELA RAMBIHOLLENDER, PETERPALMERI, MARK L. | MICROELASTIC ULTRASOUND SYSTEMS, INC., NC | $721,226 | ZRG1 |
| 2019 | Personalized Neural Stem Cell Therapy for Cancer2R42TR001789-02A1 | NICHOLS, SUSAN | FALCON THERAPEUTICS, INC., NC | $716,643 | ZRG1 |
| 2019 | Novel sanitizer/disinfectants against viral infections with long-lasting effect2R42AI124738-02 | DICKINSON, DOUGLAS PETERHSU, STEPHEN | CAMELLIX, LLC, GA | $705,771 | ZRG1 |
| 2019 | Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics2R42MH116525-02 | GHAFFARI, ROOZBEH | NEUROLUX, INC., IL | $694,703 | ZRG1 |
| 2019 | Preventing Vascular Complications in Type 1 Diabetes: Muscle Metabolic Monitoring2R42DK112497-02 | MCCULLY, KEVIN K. | INFRARED RX, INC., GA | $676,698 | ZRG1 |
| 2019 | Targeting lipid rafts for treatment of migraine1R41NS113705-01 | BACON, KEVINSORKIN, LINDA S | RAFT PHARMACEUTICALS, LLC, CA | $665,674 | ZRG1 |
| 2019 | Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.1R41NS113717-01 | CHAKRAVARTHY, KRISHNANYAKSH, TONY L. | DOULEUR THERAPEUTICS, INC., CA | $646,527 | ZRG1 |
| 2019 | Optical photothermal IR (O-PTIR) microscopy for chemical imaging of living cells at sub-micron resolution2R42CA224844-02 | CHENG, JI-XIN | PHOTOTHERMAL SPECTROSCOPY CORP., CA | $600,000 | ZRG1 |
| 2019 | Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems2R42DC015142-02 | CROSS, RUSSELL THOMASHILL, KATYA JHUGGINS, JANE E | PRENTKE ROMICH COMPANY, OH | $538,655 | ZRG1 |
| 2019 | Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission2R42AI125006-02A1 | BRENNER, DAVID JONATHANPARK, SUNG-JIN | EDEN PARK ILLUMINATION, INC., IL | $500,000 | ZRG1 |
| 2019 | Minimally Invasive Intercostal Nerve Block Device to Treat Severe Pain and Reduce Usage of Opiates1R41NS115460-01 | POPIELARSKI, STEPHENTAI, CHANGFENG | THERMAQUIL, INC., PA | $499,325 | ZRG1 |
| 2019 | In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders2R42HL136068-02 | JUNKER, LOUIS HPACE, BETTY SUEWILLIAMS, ROBERT MICHAEL | CETYA THERAPEUTICS, INC., CO | $499,220 | ZRG1 |
| 2019 | A New Non-Invasive Approach for Accessing Pulmonary Arterial Stiffness in Patients with Pulmonary Hypertension1R41HL145838-01A1 | DENNEY, THOMAS S | ARCUS-MED, LLC, NC | $488,009 | ZRG1 |
| 2019 | Novel monoclonal antibody for single dose treatment of acute CNS injury1R41NS115249-01 | CARBONELL, ANNE-MARIEKILBAUGH, TODD JUSTEN | ONCOSYNERGY, INC., CT | $456,047 | ZRG1 |
| 2019 | Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users2R42DA044788-02 | KEWEKORDES, JOSEFSHAO, XUESI MAX | AUTOMATE SCIENTIFIC, INC., CA | $453,495 | ZRG1 |
| 2019 | Developing Insulin-like growth factor binding protein 2(IGFBP2)peptide fragment-based therapeutics to treat functional and behavioral deficits in Phelan-McDermid Syndrome.1R41MH121140-01 | PENZES, PETER | ALISBIO, LLC, IL | $447,036 | ZRG1 |
| 2019 | Glioblastoma multiforme therapy via telomerase reverse transcriptase (hTERT) down-regulation. Molecular chaperones redirect quadruplex folding to reverse the effect of hTERT gene promoter mutations.1R41NS110296-01 | BERENS, MICHAEL E.HURLEY, LAURENCE H. | REGLAGENE, LLC, AZ | $401,714 | ZRG1 |
| 2019 | Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.1R41NS113694-01 | LASMEZAS, CORINNE IDA | VOVA IDA THERAPEUTICS INC, FL | $376,286 | ZRG1 |
| 2019 | Secure outsourced computation of genomic data1R41HG010978-01 | BOXWALA, AZIZ A | ELIMU INFORMATICS, INC., CA | $344,948 | ZRG1 |
| 2019 | Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy1R41NS116784-01 · under PA-17-303 | KHANNA, RAJESH | REGULONIX, LLC, NY | $341,527 | ZRG1 |
| 2019 | Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke1R41HL147676-01 | JEONG, SUN YONGREED, GUY L | TRANSLATIONAL SCIENCES, INC., AZ | $336,200 | ZRG1 |
| 2019 | Pulmonary valved conduit xenograft with regeneration potential1R41HL147771-01 | VYAVAHARE, NAREN R | ANNOVIANT, INC, GA | $314,906 | ZRG1 |
| 2019 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.1R41OD028767-01A1 | DEVENPORT, MARTINTANNO, TOSHIHIKO | ONCOIMMUNE, INC., MD | $312,714 | ZTR1 |
| 2019 | Discovery of TrkC agonist antibodies for hearing loss1R41DC018250-01 | DISTEFANO, PETER SGREEN, STEVEN H | ZEBRA BIOLOGICS, INC., MA | $304,258 | ZRG1 |
| 2019 | PIXUL-FFPE: High throughput platform for chromatin and DNA sample preparation from formalin fixed paraffin embedded (FFPE) tissue samples.1R42HG010855-01A1 | BOMSZTYK, KAROL | MATCHSTICK TECHNOLOGIES, INC., WA | $302,399 | ZRG1 |
| 2019 | Serum Inflammasome proteins: Novel biomarker panel for radiation biodosimetry1R41ES031778-01 | CHRISTOFIDOU-SOLOMIDOU, MELPOSIELECKI, THAIS | JT-MESH DIAGNOSTICS, LLC, PA | $301,260 | ZRG1 |
| 2019 | Translational development of specialized NK cells for cancer immunotherapy1R41CA235924-01 | BIGLEY, AUSTIN BASIL | INDAPTA THERAPEUTICS, INC., WA | $300,000 | ZRG1 |
| 2019 | Developing a Scalable Manufacturing Process for an Oral Bacteriophage Product that Prevents Cholera1R41AI142960-01 | CAMILLI, ANDREWYEN, MINMIN | PHAGEPRO, INC., MA | $300,000 | ZRG1 |
| 2019 | Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma1R41DE028489-01 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,000 | ZRG1 |
| 2019 | Development of a bioconjugate vaccine against Group B Streptococcus1R41AI142928-01A1 | FELDMAN, MARIO | VAXNEWMO, LLC, MO | $300,000 | ZRG1 |
| 2019 | IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma1R41AI142847-01A1 | HULL-RYDE, EMILY ARTHURRIBEIRO, CARLA MARIA PEDROSA | IREX PHARMA, LLC, NC | $300,000 | ZRG1 |
| 2019 | Aminoglycosides with reduced ototoxicity via miRNA targeting1R41AI142856-01A1 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $300,000 | ZRG1 |
| 2019 | Fully Human Antibodies for the Prevention of Respiratory Syncytial Virus1R41AI140945-01A1 | HAINES, CHARLES F | IDBIOLOGICS, LLC, TN | $300,000 | ZRG1 |
| 2019 | Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein1R41AI147929-01 | AMAN, M JAVADLI, YUXING | INTEGRATED BIOTHERAPEUTICS, INC., MD | $300,000 | ZRG1 |
| 2019 | Development of a Stem Cell-derived Cell-free Therapeutic for Stress Urinary Incontinence1R41DK122904-01 | COLEMAN, MICHAEL ELMO | THERATOME BIO, INC., IN | $300,000 | ZRG1 |
| 2019 | A New Small-Molecule Kinase Inhibitor for Airway Disease1R41HL149523-01 | HOLTZMAN, MICHAEL J | NUPEAK THERAPEUTICS, INC., MO | $300,000 | ZRG1 |
| 2019 | Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma1R41CA247044-01 | CARBONELL, ANNE-MARIEKAUR, BALVEEN | ONCOSYNERGY, INC., CT | $300,000 | ZRG1 |
| 2019 | Development of group 2 influenza A virus entry inhibitors1R41AI145727-01 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $299,999 | ZRG1 |
| 2019 | Targets of Acquired Tick-Resistance As Anti-Tick Vaccines1R41AI145778-01A1 | NARASIMHAN, SUKANYA | L2 DIAGNOSTICS, LLC, CT | $299,999 | ZRG1 |
| 2019 | Development of a vault nanovaccine for pancreatic cancer immunotherapy1R43CA221602-01A1 | BOXX, GAYLE | AUKERA, INC., CA | $299,979 | ZRG1 |
| 2019 | Novel Flexible Access Port for Extra-Cardiac Beating Heart Repair1R41HL147694-01 | DEL NIDO, PEDRO J. | NIDO SURGICAL, INC., MA | $299,948 | ZRG1 |
| 2019 | Targeting lipid rafts for treatment of asthma1R41AI147879-01 | BACON, KEVINBROIDE, DAVID H | RAFT PHARMACEUTICALS, LLC, CA | $299,940 | ZRG1 |
| 2019 | Rapid Development of a Highly Specific Dengue Diagnostic Test1R41AI141273-01A1 | WATKINS, DAVID I | Z-QUICK, LLC, FL | $299,938 | ZRG1 |
| 2019 | A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR11R41AI142846-01 | FIKRIG, EROL | L2 DIAGNOSTICS, LLC, CT | $299,888 | ZRG1 |
| 2019 | microRNA-21 Blockade of Triple Negative Breast Cancer1R41CA235707-01A1 | CASTRO, MIGUELJIN, YUAN-YUANWICKSTROM, ERIC | BOUND THERAPEUTICS, LLC, NJ | $299,774 | ZRG1 |
| 2019 | A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections1R41AI143098-01A1 | LIPKA, ELKE | TSRL, INC., MI | $299,733 | ZRG1 |
| 2019 | Noninvasive biomarkers for gastrointestinal disease in preterm infants1R41HD095779-01A1 | BUCKLEY, REBECCA SKIM, SUNYOUNG | CHOSEN DIAGNOSTICS, INC., LA | $299,641 | ZRG1 |
| 2019 | DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder1R41DA047865-01A1 | HUCKANS, MARILYNLOFTIS, JENNIFER M | VIROGENOMICS BIODEVELOPMENT, INC., OR | $299,560 | ZRG1 |
| 2019 | Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen1R41AI142829-01 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $299,248 | ZRG1 |
| 2019 | Immunization with mosquito AgTRIO protein to prevent malaria1R41AI145779-01 | FIKRIG, EROL | L2 DIAGNOSTICS, LLC, CT | $298,944 | ZRG1 |
| 2019 | Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies1R42AI143011-01A1 | PATEL, SAMIRKUMAR | MOONLIGHT THERAPEUTICS, INC., GA | $298,359 | ZRG1 |
| 2019 | Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy1R41CA233020-01A1 | DEORE, SAPNA | MEDICAL GUIDANCE SYSTEMS, LLC, MO | $296,606 | ZRG1 |
| 2019 | Detection of HIV proteins in urine to diagnose infection1R41MH122980-01 | LILLARD, JAMES W | NEWMARK DIAGNOSTICS, LLC, GA | $296,230 | ZRG1 |
| 2019 | Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury1R41DK120247-01A1 | CHOU, CHUNG-JEN JAMESZHONG, ZHI | LYDEX PHARMACEUTICALS, LLC, SC | $295,364 | ZRG1 |
| 2019 | Fully Human Antibody Combinations for the Prevention of Seasonal Influenza Infection1R41AI148019-01 | HAINES, CHARLES F | IDBIOLOGICS, LLC, TN | $294,700 | ZRG1 |
| 2019 | Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy1R41CA244011-01 | DENNER, LARRY | CORD BLOOD PLUS, INC., TX | $294,634 | ZRG1 |
| 2019 | Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia1R41AI142726-01A1 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $294,501 | ZRG1 |
| 2019 | Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK)1R41CA240124-01A1 | CANCE, WILLIAM GMARLOWE, TIMOTHY A | FAKNOSTICS, LLC, AZ | $289,594 | ZRG1 |
| 2019 | A Tissue Support Structure (Macular O-Rings) for Reconstructing, Translocating or Transplanting Three-Dimensional Submacular Tissue Organoids in Age Related Macular Degeneration (AMD)1R41EY028803-01A1 | OLSEN, TIMOTHY WAYNE | IMAC REGEN, MN | $289,064 | ZRG1 |
| 2019 | Advance Early Detection of Lupus Nephritis with ClearGold1R41DK123943-01 | YU, MENGXIAO | CLEARNANO, INC., TX | $288,365 | ZRG1 |
| 2019 | Improving HSV-2 vaccine efficacy by focusing antibody epitope coverage.1R41AI142940-01A1 | BAILEY-KELLOGG, CHRISBROOKS, BENJAMIN DELBERTCOHEN, GARY HFRIEDMAN, HARVEY MICHAEL | STEALTH BIOLOGICS, LLC, NH | $284,815 | ZRG1 |
| 2019 | Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation1R41AI142919-01 | LIU, CHANG | NEWVENTUREIQ, LLC, MO | $284,282 | ZRG1 |
| 2019 | Targeted Chelation for Reversal of Vascular Calcification1R41HL147653-01A1 | VYAVAHARE, NAREN R | ELASTRIN THERAPEUTICS, INC., SC | $283,980 | ZRG1 |
| 2019 | Direct-read monitor for airborne viral pathogens1R41AI141047-01A1 | KEADY, PATRICIA BEA | AEROSOL DEVICES, INC., CO | $279,307 | ZRG1 |
| 2019 | Novel, Potent and Metabolically Stable Oxytocin Analogues to Treat Obesity1R41DK120236-01A1 | ROTH, CHRISTIAN LUDWIG | OXT THERAPEUTICS, INC., MO | $278,866 | ZRG1 |
| 2019 | Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury1R41NS115169-01 | THOR, KARL B | DIGNIFY THERAPEUTICS, LLC, NC | $269,371 | ZRG1 |
| 2019 | Targeted Therapy for Myasthenia Gravis1R41NS110331-01A1 | KAMINSKI, HENRY J | ARC BIOTECHNOLOGY, LLC, DC | $268,669 | ZRG1 |
| 2019 | Development of an M Protein-Deficient Respiratory Syncytial Virus Vaccine for Aerosolized Vaccination of the Lung1R41AI147787-01 | WELLIVER, ROBERT C. | HEARTLAND VACCINES, LLC, OK | $267,672 | ZRG1 |
| 2019 | Automated CRISPR Screening Using the CellRaft Technology1R41GM131475-01 | BUCHSER, WILLIAM J | CELL MICROSYSTEMS, INC., NC | $267,489 | ZRG1 |
| 2019 | Beyond the pump: a novel shape memory alloy penile prosthesis1R41DK121625-01A1 | COLOMBO, ALBERTOMCVARY, KEVIN T. | URONEXT, LLC, IL | $266,922 | ZRG1 |
| 2019 | Development of mitoNEET agonists for the treatment of stroke1R41NS110070-01 | GELDENHUYS, WERNERHAZLEHURST, LORI | MODULATION THERAPEUTICS, INC., WV | $258,700 | ZRG1 |
| 2019 | Nanoentrapped polyphenol coatings for sustained release from angioplasty balloons1R41HL142403-01A1 | DUGAS, TAMMY RSABLIOV, CRISTINA M | REQUISITE BIOMEDICAL, LLC, LA | $257,732 | ZRG1 |
| 2019 | A recombinant matrix to improve autologous tissue grafts1R41CA244110-01A1 | HOLLENBECK, SCOTT THOMASROBERTS, STEFAN | INSOMA BIO, INC., NC | $254,627 | ZRG1 |
| 2019 | Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A1R41NS115184-01 | DORN, GERALD W. | MITOCHONDRIA IN MOTION, INC., MO | $254,379 | ZRG1 |
| 2019 | MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE1R41NS113642-01 | DORN, GERALD W. | MITOCHONDRIA IN MOTION, INC., MO | $254,062 | ZRG1 |
| 2019 | Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy1R41AR076871-01 | NEELAKANTAN, HARSHINI | RIDGELINE THERAPEUTICS, LLC, TX | $252,131 | ZRG1 |
| 2019 | A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing1R41GM134776-01 | BONDOS, SARAH E | BONDWELL TECHNOLOGIES, INC., TX | $248,762 | ZRG1 |
| 2019 | Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.1R41NS110252-01A1 | WARNER, DAVID | BIOMIMETIX JV, LLC, CO | $247,352 | ZRG1 |
| 2019 | Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies1R41AI145507-01 | MARATHI, UPENDRAWOODSIDE, DARREN G | 7 HILLS PHARMA, LLC, TX | $243,282 | ZRG1 |
| 2019 | Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction1R42HL144299-01A1 | HAMMOND, H. KIRK | RENOVA THERAPEUTICS, INC., CA | $241,698 | ZRG1 |
| 2019 | Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring1R41EY030403-01 | MAJID, MANI | TOROMEDES, INC., CA | $240,588 | ZRG1 |
| 2019 | The first commercial rapid diagnostic test to detect Paragonimus infections1R41AI147875-01 | BALDWIN, RICHARD KIMOBIAMONTE, MARCO ANTONIOFISCHER, PETER UWE | NANOCOMPOSIX, INC., CA | $238,810 | ZRG1 |
| 2019 | Development of a tracheal sound sensor for early detection of hypoventilation due to opioid overdose.1R41DA047779-01 | JOSEPH, JEFFREY I | RTM VITAL SIGNS, LLC, PA | $236,381 | ZRG1 |
| 2019 | Establishing a mechanistic foundation for drug discovery: The ABCA4 transporter in Stargardt Disease and other retinopathies1R41EY030401-01 | MOORE, JONATHAN | RECTIFY PHARMACEUTICALS, LLC, MA | $230,686 | ZRG1 |
| 2019 | Use of mimotope vaccine technology to develop vaccines against bacterial pathogens1R41AI145611-01 | ZHANG, GUOQUAN | ZENVAX, LLC, MO | $230,244 | ZRG1 |
| 2019 | Noregen(TM), a regenerative medicine ocular therapeutic1R41EY030807-01 | MITTON, KENNETH PATRICK | RETINAL SOLUTIONS LLC, MI | $227,051 | ZRG1 |
| 2019 | Automation and Performance-Based Selection to Improve the Reproducibility of MSCs1R44GM133291-01 | LUANGPHAKDY, VIVIANE | CELL X TECHNOLOGIES, INC., OH | $226,638 | ZRG1 |
| 2019 | Visual acuity and functional measurements in the aging eye1R41EY030829-01 | ELSNER, ANN E | AEON IMAGING, LLC, IN | $225,856 | ZRG1 |
| 2019 | LystaMab Immunotherapy to Inhibit Pericardial Adhesions1R41HL145827-01A1 | BREUER, CHRISTOPHER KANE | LYST THERAPEUTICS, LLC, OH | $225,342 | ZRG1 |
| 2019 | Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity1R41GM131533-01 | WEINBERGER, SCOT RANDY | GENNEXT TECHNOLOGIES, INC., CA | $225,285 | ZRG1 |
| 2019 | Resveratrol as a Corneal Pain Therapeutic1R41EY030804-01 | AICHER, SUE A | TED'S BRAIN SCIENCE, INC., TX | $225,005 | ZRG1 |
| 2019 | Medications for Synthetic Cannabinoid Abuse1R41DA044048-01A1 · under PA-17-303 | MAKRIYANNIS, ALEXANDROS | PAFOSPHARMA, LLC, MA | $225,000 | ZRG1 |
| 2019 | Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies1R41HL142451-01A1 | KERR, WILLIAM GARROW | ALTERNA THERAPEUTICS, INC., NC | $225,000 | ZRG1 |
| 2019 | Mobile Peer Support for Opioid Use Disorders: Refinement of an Innovative Machine Learning Tool1R41DA047837-01 | BEAUDOIN, FRANCESCA | BEACON TECH, INC., MA | $225,000 | ZRG1 |
| 2019 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)1R42HL145930-01 | GARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $225,000 | ZRG1 |
| 2019 | Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors1R41DK121587-01 | DAVIES, KELVIN PDRAGANSKI, ANDREW R | ZYLO THERAPEUTICS, INC., SC | $225,000 | ZRG1 |
| 2019 | Development of a novel accurate therapy for Multiple Sclerosis1R41AI141323-01A1 | GALARZA-MUNOZ, GADDIEL | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC., TX | $225,000 | ZRG1 |
| 2019 | Regenerative rotator cuff repair in a clinically relevant chronic disease model1R41AR074837-01A1 | EASLEY, JEREMIAH | CYTEX THERAPEUTICS INC., NC | $225,000 | ZRG1 |
| 2019 | The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients1R41HL147769-01 | GARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $225,000 | ZRG1 |
| 2019 | Rapid High-Fidelity Assembly of Challenging Peptide Sequences1R41GM133272-01A1 | KUMAR, KRISHNA | VELUM, INC., MA | $225,000 | ZRG1 |
| 2019 | Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer1R41CA235996-01A1 | CHEN, KAIEBETINO, FRANK H. | BIOVINC, LLC, CA | $225,000 | ZRG1 |
| 2019 | Oral Enzymatic Management of Phenylketonuria1R41DK122897-01 | D'MELLO, ANIL PMALONE, KENNETH GEORGE | ABRI SCIENCE, LLC, MD | $225,000 | ZRG1 |
| 2019 | Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques1R41HL147640-01A1 | LAPI, SUZANNE ELIZABETHRALPH, DAVID ALLEN | NAVIDEA BIOPHARMACEUTICALS, INC., OH | $225,000 | ZRG1 |
| 2019 | Development of a novel mobile application to assist in the diagnosis of Fetal Alcohol Syndrome (FAS)1R41AA028142-01 | CHOCKALINGAM, GANZ | BLUE RESONANCE, LLC, CA | $225,000 | ZRG1 |
| 2019 | Development of a Novel Therapeutic for Hyperthyroidism1R41DK123953-01 | RIVKEES, SCOTT A. | MEDOSOME BIOTEC, LLC, FL | $225,000 | ZRG1 |
| 2019 | An Integrative and Collaborative Genomic Data Analysis Service with Galaxy1R41HG010982-01 | AFGAN, ENIS | GALAXYWORKS, LLC, MD | $225,000 | ZRG1 |
| 2019 | STTR Phase I Development of Novel Antibacterial and Antifungal Bioadhesive Biomaterials for Diabetic Skin Wound Healing1R41DK123949-01 | FENG, MAOQI MARKYANG, JIAN | DYNAMIC ENTROPY TECHNOLOGY, LLC, TX | $225,000 | ZRG1 |
| 2019 | Associating Clinical Decision Support Use with Clinical Outcomes in a Visual Analytics Display1R41LM013317-01 | ORENSTEIN, EVAN WILLIAM | PHRASE HEALTH, INC., PA | $224,995 | ZRG1 |
| 2019 | Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency1R41AA027739-01 | CRYSTAL, RONALD G | LEXEO THERAPEUTICS, LLC, NY | $224,970 | ZRG1 |
| 2019 | Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases1R41CA239989-01A1 | LU, XIULING | NAMI THERAPEUTICS CORP., CT | $224,946 | ZRG1 |
| 2019 | Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based Intervention1R41MD014943-01 | MIDGETT, AIDA | KLEIN BUENDEL, INC., CO | $224,938 | ZRG1 |
| 2019 | Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds1R41TR002692-01 | JULIANO, RUDOLPH | INITOS PHARMACEUTICALS, LLC, NC | $224,931 | ZRG1 |
| 2019 | HIGH RECOVERY RATE AND HIGH PURITY ENRICHMENT OF CIRCULATING TUMOR CELLS1R41EB028191-01 | ZHAO, WUJUN | FCS TECHNOLOGY, LLC, GA | $224,878 | ZRG1 |
| 2019 | A Device to Inhibit Heterotopic Ossification1R41AR074337-01A1 | BAIN, STEVEN DGROSS, JEFFREY | IN SITU THERAPEUTIC SOLUTIONS, INC., WA | $224,858 | ZRG1 |
| 2019 | Drug Development for Hearing Loss1R43DC018258-01 | DHUKHWA, ASMITAMUKHERJEA, DEBASHREE | NOVEAR THERAPEUTICS LLC, IL | $224,829 | ZRG1 |
| 2019 | Optimizing membrane repair for the treatment of Duchenne muscular dystrophy1R41AR076276-01A1 | WEISLEDER, NOAH | MYOFINITY BIOSCIENCES INC, MA | $224,811 | ZRG1 |
| 2019 | Development of a Functional Assessment for Children and Youth who are Hospitalized1R41HD097844-01A1 | JETTE, ALAN MAURICEMOED, RICHARD | CRECARE, LLC, MA | $224,797 | ZRG1 |
| 2019 | A novel asthma drug candidate targeting the GABAergic system in lung inflammation1R41HL147658-01 | ARNOLD, ALEXANDER | PANTHERICS INCORPORATED, WI | $224,756 | ZRG1 |
| 2019 | Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections1R41AI145604-01 | LIN, ROBERTYANG, SAMUEL | COMBINATI, INC., CA | $224,658 | ZRG1 |
| 2019 | Advanced Multi-Modal Wearable Sensing for the Prediction of Pre-Term Labor1R41HD100284-01 | XU, SHUAI | SONICA, LLC, IL | $224,650 | ZRG1 |
| 2019 | PreImplantation Factor plus hypothermia to treat neonatal brain injury1R41HD100269-01 | BARNEA, EYTAN R | BIOINCEPT, LLC, OH | $224,648 | ZRG1 |
| 2019 | Ultrasound-coupled electrical impedance tomography for assessment of neuromuscular disorders1R41AR076912-01 | HALTER, RYAN JOSEPH | RYTEK MEDICAL, INC., NH | $224,640 | ZRG1 |
| 2019 | Gene Therapy to Protect the Lung from Oxidant Stress1R41HL145871-01A1 | CRYSTAL, RONALD G | LEXEO THERAPEUTICS, LLC, NY | $224,593 | ZRG1 |
| 2019 | Micro-endoscopic impedance sensing for surgical margin assessment1R41CA235994-01 | HALTER, RYAN JOSEPH | RYTEK MEDICAL, INC., NH | $224,572 | ZRG1 |
| 2019 | Development of a Novel Bio-Adhesive Mesh System for Abdominal Hernia Repair1R41DK120168-01 | CHAMPAIGNE, KEVIN D | CIRCA BIOSCIENCE, LLC, SC | $224,418 | ZRG1 |
| 2019 | Developing and validating a podocyte cell-based diagnostic assay for identifying recurrent focal and segmental glomerulosclerosis patients1R41DK118999-01A1 | NIHALANI, DEEPAK | INDEPTH PHARMACEUTICALS, LLC, SC | $224,281 | ZRG1 |
| 2019 | Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis1R41AI143071-01 | BALDWIN, RICHARD KIMOBIAMONTE, MARCO ANTONIO | NANOCOMPOSIX, INC., CA | $224,246 | ZRG1 |
| 2019 | A Novel remedy for periodontal bone loss1R41DE028212-01A1 | LI, XINSAXENA, DEEPAK | PERIOMICS CARE, LLC, NY | $224,101 | ZRG1 |
| 2019 | Validation of a Cranial Neurosurgery Simulator and Assessment of Minimally Invasive Techniques1R41NS115308-01 | STONE, JONATHAN JAY | SIMULATED INANIMATE MODELS, LLC, NY | $224,026 | ZRG1 |
| 2019 | Array Based Affinity Selection1R41GM134782-01 | KAY, BRIAN KENNETH | TANGO BIOSCIENCES, INC., IL | $224,009 | ZRG1 |
| 2019 | Dynasore Analogues for Ocular Surface Protection1R41EY030811-01 | FINI, M ELIZABETHLAZAROVA, TSVETELINA IVANONOVA | MEDCHEM PARTNERS, LLC, MA | $223,999 | ZRG1 |
| 2019 | Prevention of White Matter Injury in Premature Infants1R42HD097911-01A1 | RIVKEES, SCOTT A. | MEDOSOME BIOTEC, LLC, FL | $223,899 | ZRG1 |
| 2019 | Improving the Oral Bioavailability and In vivo Efficacy of a Novel TAK1 Inhibitor Targeting Rheumatoid Arthritis1R41AR076772-01 | HAYSTEAD, TIMOTHY A | EYDIS BIO, INC., NC | $223,898 | ZRG1 |
| 2019 | A2A receptor blockade for sepsis1R41AI141279-01A1 | HASKO, GEORGE | PURINE PHARMACEUTICALS, INC., NJ | $223,820 | ZRG1 |
| 2019 | Novel insulin-sensitizing NASH/diabetes drugs.1R42DK121652-01A1 | FINCK, BRIAN NPETERSON, TIMOTHY R | BIOIO, LLC, MO | $223,817 | ZRG1 |
| 2019 | An Advanced Lung Organomimetic to Reproduce Human Airway Pathophysiology1R41ES031639-01A1 | HAJIPOURAN BENAM, KAMBEZ | PNEUMAX, LLC, CO | $223,426 | ZRG1 |
| 2019 | A microfluidic device for blood analysis in neonates1R41HD100251-01 | STYBAYEVA, GULNAZ | SERSENSE, INC., MN | $223,256 | ZRG1 |
| 2019 | Development of the GlycoFibrotyper for detection of liver fibrosis1R41DK124058-01 | MEHTA, ANAND S.SCOTT, DANIELLE | GLYCOPATH, INC, SC | $223,055 | ZRG1 |
| 2019 | Continuous real-time fentanyl sensor platform based on smart hydrogels for application in anesthesia1R41GM130241-01A1 | KUCK, KAI | SENTIOMED, INC., UT | $222,921 | ZRG1 |
| 2019 | Enabling dexterous surgery at the tip of a flexible endoscope: A low-cost, disposable, steerable sheath.1R41EB028229-01A1 | WEBSTER, ROBERT JAMES | ENDOTHEIA, INC., TN | $222,874 | ZRG1 |
Showing the 200 most recent of 1,178 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.